<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146739</url>
  </required_header>
  <id_info>
    <org_study_id>PEPN2113-APAL2020C</org_study_id>
    <nct_id>NCT05146739</nct_id>
  </id_info>
  <brief_title>Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane</brief_title>
  <official_title>A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, IND #117870, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial tests the safety, side effects, and best dose of uproleselan in&#xD;
      combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia,&#xD;
      myelodysplastic syndrome, or mixed phenotype acute leukemia that has come back (relapsed) or&#xD;
      does not respond to treatment (refractory) and the expresses E-selectin ligand on the cell&#xD;
      membrane. Uproleselan binds to E-selectin expressed on endothelial cells and prevents their&#xD;
      interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell&#xD;
      activation, migration, and spreading to other places in the body (metastasis). Chemotherapy&#xD;
      drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of&#xD;
      cancer cells, either by killing the cells, by stopping them from dividing, or by stopping&#xD;
      them from spreading. Giving uproleselan in combination with fludarabine and cytarabine may&#xD;
      cause cancer to stop growing or to shrink for a period of time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose or recommended Phase 2 dose of uproleselan&#xD;
      (GMI-1271) administered in combination with fludarabine and cytarabine to patients with acute&#xD;
      myeloid leukemia (AML), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia&#xD;
      (MPAL) whose blasts express the E-selectin ligand and that are in second or greater relapse&#xD;
      or refractory to relapse therapy.&#xD;
&#xD;
      II. To characterize the pharmacokinetics and pharmacodynamics of uproleselan (GMI-1271) in&#xD;
      combination with fludarabine and cytarabine in patients with refractory and/or relapsed AML,&#xD;
      MDS or MPAL.&#xD;
&#xD;
      III. To define and describe the toxicities of uproleselan (GMI-1271) in combination with&#xD;
      fludarabine and cytarabine among patients with relapsed and/or refractory AML, MDS or MPAL.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the expression of E-selectin ligand on the surface of myeloid leukemic blasts&#xD;
      at relapse prior to initiation of uproleselan (GMI-1271) in combination with fludarabine and&#xD;
      cytarabine and at completion of the cycle.&#xD;
&#xD;
      II. To describe the antileukemic activity of uproleselan (GMI-1271) (complete remission&#xD;
      [CR]/CR with partial recover of platelet count [CRp]/CR with incomplete blood count recovery&#xD;
      [CRi] and rates of minimal residual disease (MRD) negative response after up to two cycles of&#xD;
      therapy) in combination with fludarabine and cytarabine within the limits of a Phase 1 study.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To determine the largest relative reduction in myeloid leukemic blast percentage in the&#xD;
      bone marrow, calculated from baseline at time of enrollment to up to two cycles of therapy.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of uproleselan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2022</start_date>
  <completion_date type="Anticipated">November 3, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The frequency of patients who experience a cycle 1 dose limiting toxicity stratified by study part and dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve of Uproleselan</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A descriptive analysis of the area under the plasma concentration versus time curve of Uproleselan including median, minimum and maximum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total plasma clearance of Uproleselan</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A descriptive analysis of the total plasma clearance of Uproleselan including median, minimum and maximum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life of Uproleselan</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A descriptive analysis of the elimination half-life of Uproleselan including median, minimum and maximum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of Uproleselan</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A descriptive analysis of the maximum concentration of Uproleselan including median, minimum and maximum.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental: Treatment (uproleselan, fludarabine, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive uproleselan intravenously (IV) once daily (QD) over 20 minutes on day 1 and IV over 20 minutes twice daily (BID) on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Experimental: Treatment (uproleselan, fludarabine, cytarabine)</arm_group_label>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine, 21679-14-1</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoroadenine, fludarabine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Experimental: Treatment (uproleselan, fludarabine, cytarabine)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>147-94-4</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine</other_name>
    <other_name>Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uproleselan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Experimental: Treatment (uproleselan, fludarabine, cytarabine)</arm_group_label>
    <other_name>GMI-1271</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be enrolled on APAL2020SC (NCT04726241)&#xD;
&#xD;
          -  Patients must be &lt; 18 years of age at the time of study enrollment&#xD;
&#xD;
          -  Patients, with or without Down syndrome (DS), and with de novo acute myeloid leukemia,&#xD;
             therapy-related acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype&#xD;
             acute leukemia that expresses E-selectin ligand on the cell membrane according to&#xD;
             APAL2020SC screening results and meet one of the following:&#xD;
&#xD;
               -  Second or greater relapse or refractory AML as defined below, including isolated&#xD;
                  extramedullary disease (EMD), but excluding isolated central nervous system (CNS)&#xD;
                  or isolated testicular disease&#xD;
&#xD;
               -  Second or greater relapse or refractory myelodysplastic syndrome (MDS)&#xD;
&#xD;
               -  Second or greater relapse or refractory mixed phenotype acute leukemia (MPAL)&#xD;
&#xD;
          -  Bone marrow relapse: (patients must meet one of the following criteria to be defined&#xD;
             as having relapse disease)&#xD;
&#xD;
               -  A single bone marrow sample showing &gt;= 5% leukemic blasts by flow cytometry&#xD;
                  performed at the central laboratory, fluorescence in situ hybridization (FISH)&#xD;
                  testing or other molecular method&#xD;
&#xD;
               -  A single bone marrow with at least two tests showing &gt;= 1% leukemic blasts;&#xD;
                  examples of tests include:&#xD;
&#xD;
                    -  Flow cytometry showing leukemia &gt;= 1% by multidimensional flow cytometry&#xD;
                       (MDF) performed at the central laboratory (performed at hematologics through&#xD;
                       the screening study APAL2020SC)&#xD;
&#xD;
                    -  Karyotypic abnormality with at least one metaphase similar or identical to&#xD;
                       diagnosis&#xD;
&#xD;
                    -  FISH abnormality identical to one present at diagnosis&#xD;
&#xD;
                    -  Polymerase chain reaction (PCR) or next generation sequencing (NGS)-based&#xD;
                       demonstration of leukemogenic lesion identical to diagnosis and &gt;= 1%&#xD;
&#xD;
               -  In cases where a bone marrow aspirate cannot be obtained because of extensive&#xD;
                  fibrosis, blast count can be obtained from touch imprints or estimated from an&#xD;
                  adequate bone marrow core biopsy. A complete blood count documenting the presence&#xD;
                  of at least 1,000/ uL (i.e., a white blood count [WBC] count &gt;= 10,000/uL with &gt;=&#xD;
                  10% blasts or a WBC count of &gt;= 5,000/uL with &gt;= 20% blasts) circulating leukemic&#xD;
                  cells (blasts) can also be used if a bone marrow aspirate or biopsy cannot be&#xD;
                  performed&#xD;
&#xD;
          -  Extramedullary relapse: Biopsy proven extramedullary disease after documented complete&#xD;
             remission&#xD;
&#xD;
          -  Refractory disease: Following a re-induction cycle after a second relapse, presence of&#xD;
             â‰¥1% leukemic blasts by flow cytometry performed at the central laboratory (performed&#xD;
             only at Hematologics through the screening study APAL2020SC), OR there is persistent&#xD;
             extramedullary disease&#xD;
&#xD;
          -  Patient's current disease state must be one for which there is no known curative&#xD;
             therapy or therapy proven to prolong survival with an acceptable quality of life&#xD;
&#xD;
          -  Karnofsky &gt;= 50 for patients &gt; 16 years of age and Lansky &gt;= 50 for patients =&lt; 16&#xD;
             years of age. Patients must have a performance status corresponding to Eastern&#xD;
             Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients &gt; 16&#xD;
             years of age and Lansky for patients =&lt; 16 years of age&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer therapy and must meet the following minimum duration from prior&#xD;
             anti-cancer directed therapy prior to enrollment. If after the required timeframe, the&#xD;
             numerical eligibility criteria are met, eg, blood count criteria, the patient is&#xD;
             considered to have recovered adequately&#xD;
&#xD;
               -  Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive:&#xD;
&#xD;
                    -  &gt;= 14 days must have elapsed after the completion of other cytotoxic&#xD;
                       therapy, with the exception of hydroxyurea&#xD;
&#xD;
                    -  NOTE: Cytoreduction with hydroxyurea must be discontinued &gt;= 24 hours prior&#xD;
                       to the start of protocol therapy&#xD;
&#xD;
               -  Anti-cancer agents not known to be myelosuppressive (eg, not associated with&#xD;
                  reduced platelet or absolute neutrophil count [ANC] counts): &gt;= 7 days after the&#xD;
                  last dose of agent&#xD;
&#xD;
               -  Antibodies: &gt;= 21 days must have elapsed from infusion of last dose of antibody,&#xD;
                  and toxicity related to prior antibody therapy must be recovered to grade =&lt; 1&#xD;
&#xD;
               -  Corticosteroids: If used to modify immune adverse events related to prior&#xD;
                  therapy, &gt;= 14 days must have elapsed since last dose of corticosteroid&#xD;
&#xD;
               -  Hematopoietic growth factors: &gt;= 14 days after the last dose of a long-acting&#xD;
                  growth factor (eg. pegfilgrastim) or 7 days for short acting growth factor. For&#xD;
                  agents that have known adverse events occurring beyond 7 days after&#xD;
                  administration, this period must be extended beyond the time during which adverse&#xD;
                  events are known to occur&#xD;
&#xD;
               -  Interleukins, interferons and cytokines (other than hematopoietic growth&#xD;
                  factors): &gt;= 21 days after the completion of interleukins, interferon or&#xD;
                  cytokines (other than hematopoietic growth factors)&#xD;
&#xD;
               -  Stem cell Infusions (with or without total-body irradiation [TBI]):&#xD;
&#xD;
                    -  Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem&#xD;
                       cell infusion including donor lymphocyte infusion (DLI) or boost infusion:&#xD;
                       &gt;= 84 days after infusion and no evidence of graft versus host disease&#xD;
                       (GVHD)&#xD;
&#xD;
                    -  Autologous stem cell infusion including boost infusion: &gt;= 30 days&#xD;
&#xD;
               -  Cellular Therapy: &gt;= 30 days after the completion of any type of cellular therapy&#xD;
                  (eg, modified T cells, natural killer [NK] cells, dendritic cells, etc.)&#xD;
&#xD;
               -  External beam radiation therapy (XRT)/External Beam Irradiation including&#xD;
                  protons: &gt;= 14 days after local XRT; &gt;= 150 days after TBI, craniospinal XRT or&#xD;
                  if radiation to &gt;= 50% of the pelvis; &gt;= 42 days if other substantial bone marrow&#xD;
                  (BM) radiation&#xD;
&#xD;
               -  Patients must not have received prior exposure to uproleselan (GMI-1271). NOTE:&#xD;
                  Prior therapy with fludarabine and/or cytarabine is permitted&#xD;
&#xD;
          -  For patients with leukemia:&#xD;
&#xD;
             * Platelet count &gt;= 25,000/uL (may receive platelet transfusions)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             mL/min/1.73 m^2 or a creatinine based on age/gender as follows:&#xD;
&#xD;
               -  Age: 1 month to &lt; 6 months; Maximum serum creatinine (mg/dL): 0.4 (male); 0.4&#xD;
                  (female)&#xD;
&#xD;
               -  Age: 6 months to &lt; 1 year; Maximum serum creatinine (mg/dL): 0.5 (male); 0.5&#xD;
                  (female)&#xD;
&#xD;
               -  Age: 1 to &lt; 2 years; Maximum serum creatinine (mg/dL): 0.6 (male); 0.6 (female)&#xD;
&#xD;
               -  Age: 2 to &lt; 6 years; Maximum serum creatinine (mg/dL): 0.8 (male); 0.8 (female)&#xD;
&#xD;
               -  Age: 6 to &lt; 10 years; Maximum serum creatinine (mg/dL): 1 (male); 1 (female)&#xD;
&#xD;
               -  Age: 10 to &lt; 13 years; Maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)&#xD;
&#xD;
               -  Age: 13 to &lt; 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)&#xD;
&#xD;
               -  Age: &gt;= 16 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN) for&#xD;
             age&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 225&#xD;
             U/L. For the purpose of this study, the ULN for SGPT is 45 U/L&#xD;
&#xD;
          -  Albumin &gt;= 2 g/dL&#xD;
&#xD;
          -  Shortening fraction of &gt;= 27% by echocardiogram, or ejection fraction of &gt;= 50% by&#xD;
             gated radionuclide study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following diagnoses&#xD;
&#xD;
               -  Patients with isolated central nervous system (CNS) or isolated testicular&#xD;
                  relapsed or refractory disease&#xD;
&#xD;
               -  Patients with acute promyelocytic leukemia (APL)&#xD;
&#xD;
               -  Patients with juvenile myelomonocytic leukemia (JMML)&#xD;
&#xD;
               -  Patients with a known congenital bone failure syndrome&#xD;
&#xD;
          -  Pregnant or breast-feeding women will not be entered on this study due to risks of&#xD;
             fetal and teratogenic adverse events as seen in animal/human studies, OR because there&#xD;
             is yet no available information regarding human fetal or teratogenic toxicities.&#xD;
             Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of&#xD;
             reproductive potential may not participate unless they have agreed to use two&#xD;
             effective methods of birth control, including a medically accepted barrier or&#xD;
             contraceptive method (eg, male or female condom) for the duration of the study and for&#xD;
             3 months after the last dose of uproleselan (GMI-1271). Abstinence is an acceptable&#xD;
             method of birth control&#xD;
&#xD;
          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of&#xD;
             corticosteroid for at least 7 days prior to enrollment are not eligible. If used to&#xD;
             modify immune adverse events related to prior therapy, &gt;= 14 days must have elapsed&#xD;
             since last dose of corticosteroid&#xD;
&#xD;
          -  Patients who are currently receiving another investigational drug are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving other anti-cancer agents are not eligible except&#xD;
             patients receiving hydroxyurea, which may be continued until 24 hours prior to start&#xD;
             of protocol therapy&#xD;
&#xD;
          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent&#xD;
             graft-versus-host disease post bone marrow transplant are not eligible for this trial&#xD;
&#xD;
          -  Patients who have an uncontrolled infection are not eligible&#xD;
&#xD;
          -  Patients who have received a prior solid organ transplantation are not eligible&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria L Sulis, MD</last_name>
    <phone>212-639-5175</phone>
    <email>sulism@mskcc.org</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

